A part of Watch Media

MedWatchWednesday1 February 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
02/02/2022at 09:29

Novo Nordisk aims higher than analysts in 2022 outlook

Nevertheless, 2022 won’t go as well for Novo Nordisk as 2021, the company says.
Photo: Novo Nordisk Pharmatech/PR
by marketwire, translated by daniel pedersen

In Novo Nordisk’s full-year financial report, which was released on Wednesday morning, the Danish pharmaceutical giant predicts less growth in 2022 than what it just booked in 2021. The company also estimates that its 2022 sales growth will land in the 6–10 percent range in constant exchange rates (CER) compared to 14 percent in 2021, while the operating profit growth will be between 4–8 percent at CER against the reported 13 percent in 2021.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: Stine Tidsvilde

    Novo Nordisk had a record-breaking 2021 profit, but has reined in expectations for 2022

    For subscribers

  • Photo: Stine Tidsvilde

    All eyes on Novo's new outlook on eve of 2021 report

    For subscribers

  • Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

    Swedish bank slashes Novo Nordisk price target ahead of 2022 outlook

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Arnd Wiegmann/Reuters/Ritzau Scanpix
Pharma & biotech

Novartis beats Kesimpta sales expectations in Q4

Multiple sclerosis treatment Kesimpta, based on Genmab-developed ofatumumab, has generated more than analysts predicted in Q4’22.
  • Janssen's books disappointing sales of Genmab-developed Darzalex
  • Denmark rejects Janssen and Genmab drug twice in January

For subscribers

Foto: Andrew Kelly/Reuters/Ritzau Scanpix
Pharma & biotech

Analyst: Strong Novo Nordisk outlook should satisfy investors

For subscribers

Foto: Jens Dresling/Ritzau Scanpix
Pharma & biotech

Studies of Wegovy in higher-than-approved doses begin

For subscribers

Foto: Novo Nordisk
Pharma & biotech

Rare Disease business comes in slightly below expectations for Novo Nordisk

For subscribers

Foto: Novo Nordisk / Pr
Pharma & biotech

Novo Nordisk doubles obesity sales in 2022

For subscribers

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk meets upgraded guidance, setting new revenue record

For subscribers

Further reading

Foto: Robert Galbraith/Reuters/Ritzau Scanpix
Pharma & biotech

Amgen takes on Abbvie blockbuster Humira with unusual price plan

Abbvie’s multibillion-dollar generating anti-inflammatory drug, Humira, is about to face competition for the first time, as Amgen launches an almost identical product using an unconventional strategy.

For subscribers

Foto: Lukas Barth/Reuters/Ritzau Scanpix
Pharma & biotech

Bank raises expectations for Bavarian Nordic's 2023 outlook

Danske Bank believes Bavarian Nordic is well on the way to secure another record-breaking year after having seen preliminary figures for the drugmaker’s 2022 performance on Monday.

For subscribers

Foto: Philip Davali
Pharma & biotech

Bavarian Nordic ditches debt refinancing: "We don’t need the money right now"

Orders for the Danish drugmaker’s mpox vaccine have put the company in a way better position than was expected at the beginning of 2022, says Bavarian Nordic CFO Henrik Juuel. 

For subscribers

Latest news

  • Novartis beats Kesimpta sales expectations in Q4 – 11:49
  • Analyst: Strong Novo Nordisk outlook should satisfy investors – 11:09
  • Studies of Wegovy in higher-than-approved doses begin – 10:01
  • Rare Disease business comes in slightly below expectations for Novo Nordisk – 09:48
  • Novo Nordisk meets upgraded guidance, setting new revenue record – 09:20
  • Novo Nordisk doubles obesity sales in 2022 – 08:54
  • Maersk and German start-up wants to enhance emission visibility for global e-trade – 08:27
  • Novo Nordisk predicts wide range for 2023 sales growth – 07:38
  • Pfizer hopes Covid-19 sales will increase in the long run – 31 Jan
  • Amgen takes on Abbvie blockbuster Humira with unusual price plan – 31 Jan
See all

Jobs

  • Head of Regulatory Affairs Danmark

  • Lead Data Architect

  • Senior Regulatory Affairs Professional

  • Clinical Operational Associate

  • Sr. Director, Drug Safety Physician

  • Commercial Director

  • Application Manager

  • Application Manager

  • Regulatory Affairs Professional

  • Experienced Patent Counsel

  • Specialist for the supply of pharmaceuticals to Danish hospitals

See all jobs

Jobs

  • Head of Regulatory Affairs Danmark

  • Lead Data Architect

  • Senior Regulatory Affairs Professional

  • Clinical Operational Associate

  • Sr. Director, Drug Safety Physician

  • Commercial Director

  • Application Manager

  • Application Manager

  • Regulatory Affairs Professional

  • Experienced Patent Counsel

  • Specialist for the supply of pharmaceuticals to Danish hospitals

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge